Magnetic Blood Filtration” (MBF) is a first-of-its-kind drug/device combination platform that enables the removal of specific substances from the bloodstream. MBF can be used either as a direct treatment, to increase the safety and efficacy of other therapies, or enable personalised medicine. We have the ambition to become a global player, providing hospitals with a new tool to tackle some of mankind’s most serious diseases.

Keep In Touch

A spin-out from University College London, MediSieve is a multi-award-winning company dedicated to the development and commercialisation of MBF. The company has raised a total of £4M in equity funding and won grants worth a total of over £4M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. We closed a £1.8M Series A in May 2021, and in December 2020 secured a £1.6M grant from the UKRI to support clinical trials, which are due to start in 2021.

Our multidisciplinary team has experience across various fields of science and technology development.

 

MediSieve raises additional £1.8 million in funding

MediSieve raises additional £1.8 million in funding
June 24, 2021

MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today announced a £1.8m investment, led by 24Haymarket. This investment will fund first-inman trials investigating the safety and efficacy of the company’s pivotal IL-6 product. MediSieve has developed ...
MediSieve selected for the London & Partners’ Business Growth Programme

MediSieve selected for the London & Partners’ Business Growth Programme
June 05, 2020

MediSieve was accepted onto the London & Partners’ Business Growth Programme! The free, three-month programme is giving London-based companies the tools they need to survive and thrive during these challenging times - from mentorship and account management, to expert advice and new business opportu...